Replication FailureOpen accessMedicine· cited by 104

Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease

Manaf AlQahtani; Abdulkarim Abdulrahman; Abdulrahman Almadani; Salman AlAli; Alaa Mahmood Al Zamrooni; Amal Hejab; Ronán Conroy; Pearl Wasif · 2021 · Scientific Reports

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

Convalescent plasma (CP) therapy in COVID-19 disease may improve clinical outcome in severe disease. This pilot study was undertaken to inform feasibility and safety of further definitive studies. This was a prospective, interventional and randomized open label pilot trial in patients with severe COVID-19. Twenty COVID-19 patients received two 200 ml transfusions of convalescent patient CP over 24-h compared with 20 who received standard of care. The primary outcome was the requirement for ventilation (non-invasive or mechanical ventilation). The secondary outcomes were biochemical parameters

Abstract by Manaf AlQahtani; Abdulkarim Abdulrahman; Abdulrahman Almadani; Salman AlAli; Alaa Mahmood Al Zamrooni; Amal Hejab; Ronán Conroy; Pearl Wasif, Scientific Reports (2021) — licensed CC BY 4.0.

Read the full paper (open access)